Nisha Panday
Acute Care · Greenville, OHNPI 1124484399
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 263 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,575 and has fallen 83.3% since, to $263 in 2025. Among acute care clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 263 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$692
- Amgen$465
- Amarin Pharma, Inc.$422
- Boehringer Ingelheim$418
- Actelion Pharmaceuticals US, Inc.$379
- Merck$298
- plus $2K from 22 others
What the payments were for
- Food & beverage$4,27299%
- Education$411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 44 | $692 |
| Amgen | 25 | $465 |
| Amarin Pharma, Inc. | 29 | $422 |
| Boehringer Ingelheim | 27 | $418 |
| Actelion Pharmaceuticals US, Inc. | 27 | $379 |
| Merck | 18 | $298 |
| Johnson & Johnson | 18 | $284 |
| Boston Scientific | 12 | $213 |
| Bayer | 9 | $163 |
| Novo Nordisk | 9 | $161 |
| Pfizer | 10 | $150 |
| Alnylam Pharmaceuticals Inc. | 4 | $86 |
| Philips North America LLC | 4 | $70 |
| Impulse Dynamics (USA) Inc. | 1 | $65 |
| AstraZeneca | 3 | $61 |
| Sanofi-aventis U.S. LLC | 4 | $58 |
| Kowa Pharmaceuticals America, Inc. | 3 | $48 |
| Esperion Therapeutics, Inc. | 2 | $44 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Medtronic | 2 | $32 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $26 |
| Abbott | 1 | $25 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $24 |
| Bridgebio Pharma, Inc. | 1 | $21 |
| Scpharmaceuticals Inc. | 1 | $21 |
| GSK | 1 | $18 |
| Chiesi USA, Inc. | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$4,313 in reported general payments places this provider in the 95th percentile of 1,101 acute care providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 111 | $94,710 |
| EntrestoSacubitril/Valsartan | 14 | $12,977 |
| XareltoRivaroxaban | 15 | $12,386 |
| BrilintaTicagrelor | 11 | $4,946 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 75 | $1,338 |
| Amiodarone Hcl | 46 | $1,083 |
| Metoprolol Succinate | 114 | $955 |
| ClopidogrelClopidogrel Bisulfate | 93 | $863 |
| Potassium Chloride | 58 | $737 |
| Metoprolol Tartrate | 182 | $723 |
| Atorvastatin Calcium | 97 | $676 |
| Flecainide Acetate | 20 | $666 |
| Midodrine Hcl | 20 | $570 |
| Furosemide | 142 | $558 |
| Amlodipine Besylate | 115 | $554 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $150 | $94,710111 claims |
| NovartisEntresto | $692 | $12,97714 claims |
| Johnson & JohnsonXarelto | $284 | $12,38615 claims |
| AstraZenecaBrilinta | $61 | $4,94611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,101 acute care providers in Ohio.
Other acute care in Greenville
- Andrea RobinsonCleveland$149K
- Brittney BrowneMonroe$142K
- Jamie McGuireMiamisburg$86K
- Ileah ReichertColumbus$73K
- Davida PraterBeavercreek$46K
- Dawn FrenchAlliance$40K
- Holly McKibbenColumbus$23K
- Jody HussBlue Ash$13K
- Julie LurieCincinnati$13K
- Susan BrooksMount Vernon$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.